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Summary
BCL-2 proteins are critical for cell survival and are overexpressed inmany tumors. ABT-737 is a small-molecule BH3mimetic
that exhibits single-agent activity against lymphoma and small-cell lung cancer in preclinical studies. We here report that
ABT-737 effectively kills acute myeloid leukemia blast, progenitor, and stem cells without affecting normal hematopoietic
cells. ABT-737 induced the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of
the intrinsic apoptotic pathway. In cells with phosphorylated BCL-2 or increased MCL-1, ABT-737 was inactive. Inhibition
of BCL-2 phosphorylation and reduction of MCL-1 expression restored sensitivity to ABT-737. These data suggest that
ABT-737 could be a highly effective antileukemia agent when the mechanisms of resistance identified here are considered.Introduction
Aberrant overexpression of BCL-2 is associated with tumori-
genesis and increased resistance to chemotherapy in multiple
malignancies, including acute myeloid leukemia (AML) (Campos
et al., 1993; Vaux et al., 1988). Similar findings have been made
for other antiapoptotic members of the BCL-2 family, such as
BCL-XL and MCL-1 (Fennell et al., 2001; Kaufmann et al.,
1998). BCL-2 is a potent antiapoptotic protein that protects cells
from diverse stress challenges including chemotherapeutic
drugs. A key function of BCL-2 is to act as guardian ofmitochon-
drial integrity by opposing proapoptotic BCL-2 family members
(Oltvai et al., 1993; Korsmeyer et al., 1993; Sedlak et al., 1995;
Sharpe et al., 2004). BCL-2 function depends on posttransla-
tional modification, whereby phosphorylation of BCL-2 can
either promote (May et al., 1994; Deng et al., 2004) or inhibitCANCER CELL 10, 375–388, NOVEMBER 2006 ª2006 ELSEVIER INC. DO(Haldar et al., 1998; Srivastava et al., 1998) its antiapoptotic
function.
Antiapoptotic BCL-2 family proteins are normally kept in
check by endogenous antagonists that contain a conserved
dimerization motif termed BH3 (Oltvai et al., 1993; Zha et al.,
1996). The BH3 domain consists of an amphipathic a helix
that binds a hydrophobic groove on antiapoptotic BCL-2 family
members, negating their cytoprotective activity (Fesik, 2000).
Proof of concept experiments using BH3 peptides have sug-
gested that docking at the BH3 domain of BCL-2 and its related
antiapoptotic proteins could deactivate BCL-2 to increase the
sensitivity of tumor cells to apoptosis. Indeed, several small-
molecule chemicals have been identified that bind to BCL-2
family proteins by interacting with the BH3-binding groove and
promote apoptosis (Pellecchia and Reed, 2004). ABT-737 is
a synthetic small-molecule inhibitor produced by NMR-guided,S I G N I F I C A N C E
BCL-2 family proteins are key regulators of apoptosis and are known to promote tumorigenesis and chemoresistance. Strategies to
target BCL-2 could translate into effective anticancer therapies. We investigated mechanisms of action of the BCL-2 (BH3) inhibitor
ABT-737 and found that ABT-737 disrupts BCL-2/BAX heterodimers and induces apoptosis in AML stem cells through activation of the
intrinsic apoptotic pathway. ABT-737 synergized with chemotherapy, but its activity was largely diminished in cells overexpressing
MCL-1 or displaying phosphorylated BCL-2. Reducing MCL-1 levels and suppressing BCL-2 phosphorylation potentiated ABT-737-
induced apoptosis. Furthermore, the agent was effective in vivo. These findings suggest that ABT-737may be an effective antileukemia
agent with a unique mode of action.I 10.1016/j.ccr.2006.10.006 375
A R T I C L Estructure-based drug design that binds BCL-2, BCL-XL, and
BCL-W with high affinity (Ki < 1 nM) but binds weakly (Ki >
460 nM) to other antiapoptotic BCL-2 family members, including
MCL-1 and BFL-1 (Oltersdorf et al., 2005). In a cell-free system
of purified mitochondria, the inhibitor antagonized the antiapop-
totic function of BCL-2 and BCL-XL but did not directly activate
BAX or BAK (Oltersdorf et al., 2005).
In the current study, we report that ABT-737 can promote ap-
optosis as a single agent in cells from AML-derived cell lines,
and in primary blasts from AML patients. The drug inhibited
growth of clonogenic AML progenitor and stem cells and was
effective in vivo in a xenograft model of AML. We demonstrated
that ABT-737 disrupts BCL-2/BAX association in leukemia cells
and promotes activation of BAX and mitochondrial dysfunction
in these cells, in part through BAK. High MCL-1 expression and
BCL-2 phosphorylationmarkedly reduced the ability of ABT-737
to induce apoptosis. The inhibition of MEK1/ERK is highly syner-
gistic with ABT-737 in killing leukemia cells via suppression of
BCL-2 phosphorylation and downregulation of MCL-1 levels in
AML. The criticality of MCL-1 as a resistance factor to ABT-
737 was established by MCL-1 small interfering RNA (shRNA)
knockdown, which completely restored sensitivity in leukemic
cells that were resistant to ABT-737 alone. These findings dem-
onstrate the potential of ABT-737 as a mechanism-based ther-
apeutic agent, whose activity can be further enhanced by target-
ing the resistance factors described in this report.
Results
ABT-737 induces apoptosis and synergizes
with chemotherapy in AML cells
ABT-737 was created as a small-molecule chemical that would
bind the BH3-binding groove of BCL-XL and BCL-2 (Oltersdorf
et al., 2005). Using competitive fluorescence polarization assays
(FPAs), we compared the affinity of ABT-737 to various antia-
poptotic BCL-2 family members. ABT-737 was shown to com-
pete with the fluorochrome-conjugated BIM BH3 peptide for
binding to BCL-XL, BCL-2, BCL-W, and to a lesser degree,
BCL-B, but not to MCL-1 and BFL-1 (Figure 1A). We next exam-
ined effects of ABT-737 and its less active enantiomer (Olters-
dorf et al., 2005) on the viability of AML cell lines with different
basal expression of BCL-2 family proteins (Figures 1B–1D).
The IC50 for the inactive enantiomer in all cell lines was at least
10-fold higher as compared to the respective IC50 for ABT-737
(data not shown and Figures 1C and 1D). HL-60 cells displayed
the greatest sensitivity to the compound (IC50 = 50 nM), while
OCI-AML3 cells were the most resistant (IC50 = 5000 nM).
MCL-1 expression was highest in the two cell lines (U937 and
OCI-AML3) that exhibited the greatest resistance to the com-
pound (Figure 1B). Since ABT-737 binds poorly to MCL-1
(Figure 1A and Oltersdorf et al., 2005), the possibility arises
that MCL-1 may substitute for BCL-2 or BCL-XL and thus confer
resistance.
HL-60 cells treated with ABT-737 (100 nM) exhibited classic
signs of apoptosis: early (within 1 hr) loss of mitochondrial mem-
brane potential (Dcm), followed by phosphatidyl serine exter-
nalization as indicated by Annexin V staining (at 12–24 hr;
Figure 1E), DNA fragmentation as indicated by DNA laddering
(data not shown), and finally loss of viability (at 24–48 hr;
Figure 1C). ABT-737 had no effect on cell cycle distribution376(data not shown). These data indicate that in AML cells ABT-
737 can induce apoptosis as a single agent.
To determine if the inhibition of BCL-2 and/or family members
might potentiate the effects of chemotherapeutic regimens used
in the treatment of AML, OCI-AML3 cells were treated with ABT-
737 for 24 hr before the addition of Ara-C (IC50 = 3.64 mM) or Dox
(IC50 = 0.17 mM). The combination of ABT-737 and Ara-C in
these cells, which are relatively resistant to ABT-737, Ara-C,
and Dox, individually revealed synergistic effects on apoptosis
induction, with an average combination index (CI) of 0.57 6
0.05 (Figure 1F). Similarly, the combination of ABT-737 and
Dox synergistically induced apoptosis with an average CI of
0.37 6 0.01 (Figure 1G). Simultaneous treatment with ABT-737
and chemotherapeutic agents yielded essentially identical re-
sults (CI of ABT-737 and Ara-C cotreatment in OCI-AML3 cells,
0.41 6 0.006). These results demonstrate that ABT-737 syner-
gizes potently with both Ara-C and Dox in AML cells.
ABT-737 disrupts BCL-2/BAX heterodimerization and
induces BAX conformational change in AML cells
A classic model of BCL-2 function suggests that the noncova-
lent heterodimerization of BCL-2 and BAX serves to quench
BAX’s apoptotic function by inhibiting proapoptotic BH3-only
family members from activating BAX (Chen et al., 2005; Kuwana
et al., 2005;Oltvai et al., 1993). TheBCL-2/BAX complexwas im-
munoprecipitated using a BAX antibody from cell lysates disrup-
ted in 1% CHAPS lysis buffer, since a previous report indicated
that the nonionic detergent NP-40 may alter BAX conformation
and affect the BCL-2/BAX interaction (Hsu and Youle, 1997).
As a control for dimerization studies, we used HeLa cells, in
which no BAX/BCL-2 dimerization was detected using CHAPS
buffer, consistent with published reports (Figure 2A) (Wolter
et al., 1997; Hsu et al., 1997). In contrast, in DMSO- or enantio-
mer-treated HL-60 leukemic cells, abundant amounts of BCL-2
are coimmunoprecipitated with BAX, and this BCL-2/BAX asso-
ciation was effectively disrupted by ABT-737 (Figure 2B). Curi-
ously, even though the total amount of BAX did not change,
the amount of BAX being immunoprecipitated increased in
ABT-737-treated cells, possibly reflecting more efficient recog-
nition of BAX by polyclonal antibody after disruption of BCL-2/
BAX complex. These findings suggest that ABT-737-induced
cell death is associated with decreased BCL-2/BAX heterodi-
merization. Similar results were obtained when cells were
disrupted in 0.5% NP-40 lysis buffer (data not shown). This
inhibition of BCL-2/BAXassociation occurs 1 and 3 hr after treat-
ment with ABT-737, concomitant with cytochrome c release but
prior to cleavage of caspase-3, caspase-8, or BCL-2 and BAX
itself (Figure 2C).
Recent studies have indicated that activated BAX assumes
a specific structure that can be identified by an antibody that
recognizes its ‘‘prodeath’’ conformation. As shown in Figure
2D, untreated cells display BAX but not in the prodeath confor-
mation. After treatment with ABT-737, prodeath BAX is readily
detectable, indicating that the compound promotes conforma-
tional changes in BAX that are associated with apoptosis. No
change in either BCL-2/BAX association or BAX conformation
was seen after treatment with the inactive enantiomer (Figures
2B and 2D).
While nonionic detergents may artificially promote BCL-2/
BAX interaction (Hsu and Youle, 1997), a recent report demon-
strated that BCL-2/BAX complexes may indeed exist at theCANCER CELL NOVEMBER 2006
A R T I C L EFigure 1. ABT-737 inhibits cell growth and induces apoptosis in leukemic cells
A: Competition inhibition of GST-BCL-2 family fusion protein binding to FITC-BIM BH3 peptide by ABT-737. BCL-2 proteins (100 nM) including BCL-XL, BCL-2,
BCL-W, BCL-B, BFL-1, and MCL-1were incubated with ABT-737 for 2 min in PBS buffer. FITC-conjugated-BIM BH3 peptide (20 nM) was added, and fluorescence
polarization was measured after 10 min.
B: Basal expression levels of BCL-2 family members in leukemic cell lines was examined by western blotting, and the intensity of the bands relative to that in
HL-60 cells was quantified by densitometry. The effect of ABT-737 on the viability of leukemic cells was determined at 72 hr, and IC50s were calculated using
CalcuSyn software.
CandD: Exponentially growing HL-60 cells were treated with indicated concentrations of ABT-737 (C) or its inactive enantiomer (D), and effects on cell growth
were assessed by viable cell counts at 24, 48, and 72 hr.
E: Phosphatidylserine externalization in HL-60 cells was determined by Annexin V staining, and reduction in mitochondrial membrane potential (Dcm) was
determined by decrease in TMRM fluorescence. Results are expressed as mean 6 SEM of three independent experiments.
F and G: OCI-AML3 cells were cultured in the presence of escalating doses of ABT-737 (100, 250, 500, and 1000 nM), Ara-C (F, 0.25, 0.625, 1.25, and 2.5 mM),
doxorubicin (G, 0.025, 0.05, and 0.1 mM), or combinations of the two agents at a fixed (1:1) ratio. After 48 hr, apoptosis was measured by Annexin V flow
cytometry. CI plots were then generated using the Chou-Talay method and Calcusyn software.mitochondria and that mitochondrial BAX could be co-
immunoprecipitated with BCL-2 using CHAPS detergent lysis
(Zhou et al., 2005). To determine the composition of leukemic
cell mitochondria, we assessed BAX expression in purifiedmito-
chondria from HL-60 cells. BAX was abundantly expressed in
the mitochondrial fraction; however, it appeared to be loosely
associated with HL-60 mitochondria, since the supernatants
from isolated mitochondrial fractions contained similar or even
higher amounts of BAX than the mitochondria (Figure 2E). The
proapoptotic BH3-only protein BIM was detected almost exclu-
sively in the mitochondrial fraction, consistent with recent re-
ports in other hematopoietic cell lines (Zhu et al., 2004; HaradaCANCER CELL NOVEMBER 2006et al., 2004), demonstrating that leukemic cell mitochondria con-
tain components of the proapoptotic machinery required for
triggering mitochondrial permeability transition. Consistent
with this scenario, ABT-737 induced cytochrome c release
from purified mitochondria (Figure 2E).
To determine if ABT-737-induced apoptosis requires BAX,
a well-characterized BAX knockout cell line (HCT116) was
used. Parental cells were sensitive to 10 mM ABT-737 with ap-
proximately 80% cell death after 72 hr. The BAX knockout vari-
ant, however, was completely resistant to the drug (Figure 2F).
To determine the requirement of BAK in ABT-737-induced cell
death, we compared effects of ABT-737 in WT, BAX, BAK, or377
A R T I C L EFigure 2. ABT-737 disrupts BCL-2/BAX heterodimerization and induces BAX conformational change in AML cells
A: Endogenous BCL-2 does not bind endogenous BAX in HeLa cells. Healthy HeLa cells were lysed in buffer containing 1% CHAPS. Immunoprecipitation was
then performed with an anti-BAX antibody and examined for the presence of BCL-2. First lane: lysate of untreated HeLa cells. Lower panel: expression of BCL-2
and BAX in cell lysates prior to immunoprecipitation.
B: BAX was immunoprecipitated from HL-60 cells treated for the indicated time points with 100 nM ABT-737, and immunoprecipitates (CHAPS buffer) were
subjected to western blot analysis using anti-BCL-2 antibody. The amount of BAX immunoprecipitated from each sample was determined using anti-BAX
antibody. IgL, immunoglobulin light chain.
C: Cleavage of caspase-3, -8, and -9, cytosolic release of cytochrome c, and expression of BCL-2 and BAX after ABT-737 treatment were assessed by western
blot.378 CANCER CELL NOVEMBER 2006
A R T I C L Edouble knockout (DKO) mouse embryonic fibroblasts (MEFs).
While ABT-737 induced apoptosis in WT MEFs, induction of ap-
optosis wasminimal in cells deficient in either BAX, BAK, or both
(Figure 2G). These data indicate that ABT-737-induced killing re-
quires both BAX and BAK. To further establish the role of BAK in
ABT-737-induced apoptosis of leukemic cells, we treatedHL-60
cells transfected with a pool of siRNAs targeting BAK or with
control siRNAs with increasing concentrations of ABT-737. Re-
markably, knockdown of BAK expression by 50% resulted in
significant blockade of ABT-induced mitochondrial depolariza-
tion determined by loss of TMRM fluorescence (Figure 2H), and
a less pronounced inhibition of staurosporine- or etoposide-
induced MMP loss.
BIM is traditionally characterized as a direct ‘‘activator’’ of
BAX/BAK, and in certain experimental systems these BH3-
only proteins are required for activation of BAX and BAK and
subsequent mitochondrial permeability (Letai et al., 2002; Ku-
wana et al., 2005). However, because antiapoptotic proteins
can sequester these direct activator BH3-only proteins, neutral-
ization of the antiapoptotic proteins may be necessary for apo-
ptosis to occur. Based on the finding of themitochondrial, rather
than microtubular, localization of the BH3-only protein BIM in
leukemic cells, we examined the potential role of BIM in ABT-
737-induced apoptosis utilizing a siRNA approach. Knockdown
of BIM isoforms of up to 70% did not significantly affect ABT-
737-induced apoptosis (Figure S1 in the Supplemental Data
available with this article online) but did inhibit Taxol-induced
cell death, consistent with published reports (Tan et al., 2005).
Inhibition of BCL-2 phosphorylation enhances
ABT-737-induced apoptosis
BCL-2 phosphorylation may also play a role in determining sen-
sitivity to ABT-737 since the antiapoptotic function of BCL-2 is
regulated by phosphorylation (May et al., 1994; Haldar et al.,
1998; Srivastava et al., 1998; Deng et al., 2000). ERK was iden-
tified as a BCL-2 kinase, and we reported that MEK1 inhibitor
PD98059 (Figure 3A) potently suppresses BCL-2 phosphoryla-
tion and sensitizes cells to apoptosis (Deng et al., 2000; Kono-
pleva et al., 2002). OCI-AML3 cells treated with PD98059
show potent inhibition of BCL-2 phosphorylation (Figure 3B).
The combination of PD98059 and ABT-737 was highly synergis-
tic in killing leukemic cells (CI = 0.08 6 0.003) (Figure 3C).
These data suggest that BCL-2 phosphorylation modulates
sensitivity of AMLs to ABT-737. To further explore this mecha-
nism, BCL-2 phosphorylation mutants were employed. InCANCER CELL NOVEMBER 2006NSF/N1.H7 murine myeloid cells, conversion of the reported
phosphorylated sites in BCL-2 (i.e., threonine 69, serine 70,
and serine 87) to alanine residues (AAA mutant) results in in-
creased apoptosis sensitivity. In contrast, conversion of the
three amino acid residues to glutamate residues (EEE) produces
a gain-of-functionmutant that protects cells fromAra-C and eto-
poside (Deng et al., 2004). Our experiments demonstrated that
BCL-2 phosphomimetic (EEE) NSF/N1.H7 cells are more resis-
tant to ABT-737 than cells expressing WT BCL-2 (Figure 3D),
suggesting that BCL-2 phosphorylation opposes the proapop-
totic action of ABT-737. Consistent with a mechanism whereby
increased BCL-2 phosphorylation impedes ABT-737 suppres-
sion of BCL-2 dimerization with BAX, ABT-737 potently blocked
BCL-2/BAX association in cells expressing exogenousWTBCL-
2 and AAA mutant, but not EEE mutant BCL-2 (Figure 3E).
Suppression of MCL-1 expression enhances
ABT-737-induced apoptosis
As indicated in Figure 1B, MCL-1 expression levels correlated
with sensitivity to the drug. Compared to BCL-2, MCL-1 has a
short half-life that is regulated by ERK phosphorylation of a
PEST sequence (Schubert and Duronio, 2001). Inactivation of
ERK massively enhanced ABT-737-induced apoptosis (CI <
0.1) (Figure 3C). At least part of this synergism likely involves
loss of ERK as a BCL-2 kinase. However, loss of MCL-1 expres-
sion as result of ERK suppression may also contribute to the ob-
served synergism, and PD98059 indeed downregulated MCL-1
in OCI-AML3 cells (Figure 4A). Prolonged ABT-737 exposure in-
ducedmodest increase ofMCL-1 expression, likely as a result of
the death of lowMCL-1-expressing cells, and PD98059 potently
suppressed expression of this antiapoptotic protein (Figure 4A).
To confirm the inability of ABT-737 to inhibit MCL-1 function
that was demonstrated by FPA (Figure 1A), coimmunoprecipita-
tion assays were performed. As shown in Figure 4B, when BIM
or BAKwas immunoprecipitated fromOCI-AML3 cells, coimmu-
noprecipitation of MCL-1 was unimpaired in ABT-737-treated
cells. In contrast, ABT-737 effectively disrupted BCL-2/BAX
and BCL-2/BIM association in these cells (Figure 4B, BAX IP
and BCL-2 IP). No association of MCL-1 with BAX was found
in these cells either before or after ABT-737 (data not shown).
On the contrary, in ABT-737-sensitive HL-60 cells, no detect-
able MCL-1 was found in BAK or BIM complexes (Figure S2).
To test the hypothesis that MCL-1 expression modulates
ABT-737 cytotoxicity, MCL-1 levels were reduced in OCI-
AML3 cells using shRNA. Infection with lentiviral bicistronicD: Protein lysates from HL-60 cells treated for the indicated time points with 100 nM ABT-737 were subjected to immunoprecipitation using anti-BAX antibody
clone 6A7, which recognizes only conformationally changed BAX protein. Supernatants (Sup) and immunoprecipitates (IP) were subjected to western blot
analysis with anti-BAX antibody.
E: Mitochondria of HL-60 cells were isolated as described in the Experimental Procedures, resuspended in M buffer at 0.8 mg/ml protein, and equilibrated at
room temperature for 2 min prior to the addition of ABT-737. The concentration of DMSO did not exceed 0.2%. Mitochondrial suspensions were incubated for
15 min at room temperature, and mitochondria were collected by centrifugation at 14,000 rpm for 5 min. The presence of cytochrome c, BIM, and BAX was
evaluated by western blotting of the mitochondrial pellet and the supernatant. The purity of mitochondrial preparations was assessed by COXIV immunoblot-
ting. The amount of ABT-737 per milligram of mitochondrial protein used in these experiments is comparable to the amount of ABT-737 used per milligram of
protein in cell culture experiments (4–10 nmol/mg protein).
F: HCT116 BAX+/2 and HCT116 BAX2/2 cells were treated with the indicated concentrations of ABT-737 for 48 hr. Western blot shows levels of BAX in +/2
and 2/2 HCT116 cells.
G: WT and DKO SV40-MEFs were cultured in DMEM medium supplemented with 10% FCS for 72 hr with or without 100 nM ABT-737 and its enantiomer control.
Apoptosis was evaluated by Annexin V staining. Results are expressed as mean 6 SEM of three independent experiments.
H: Depletion of BAK by siRNA preserves mitochondrial integrity in ABT-737-treated leukemic cells. HL-60 cells transfected with a pool of BAK siRNAs or control
siRNA by Amaxa nucleofection were treated with the indicated concentrations of ABT-737, staurosporine (STS), etoposide (Eto), or 400 nM enantiomer for
24 hr, and loss of the mitochondrial membrane potential was determined by TMRM fluorescence. Statistically significant differences were determined by
ANOVA test (*p < 0.05; **p < 0.01). BAK expression was examined by western blotting, and the intensity of the bands relative to that in mock-transfected
HL-60 cells was quantified by densitometry. Results are expressed as mean 6 SEM of three independent experiments.379
A R T I C L EFigure 3. Inhibition of BCL-2 phosphorylation enhances ABT-737-mediated apoptosis
A: Inhibition of ERK signaling by PD98059 in OCI-AML3 cells was determined by ERK kinase assay. MAP kinase activity was measured by the ability to phosphor-
ylate the specific substrate, MBP, in the in vitro kinase assay. Total ERK immunoblot was used as a loading control.
B: OCI-AML3 cells were radiolabeled with [32P]orthophosphate, treated with 10 and 25 mM PD98059, and lysed, after which BCL-2 was immunoprecipitated.
Protein was subjected to SDS/PAGE, transferred to nitrocellulose membrane, and exposed to X-ray film to identify phosphorylated BCL-2. The identity of the
protein was confirmed by western blot analysis using the same filter.
C: OCI-AML3 cells were cultured in the presence of escalating doses of ABT-737 (100, 250, 500, and 1000 nM) and PD98059 (2.5, 5, 10, and 25 mM) or combi-
nations of the two agents at a 1:25 ratio. After 72 hr, apoptosis was measured by Annexin V flow cytometry, and CI plots were generated. Results are expressed
as mean 6 SEM of three independent experiments.
D:NSF.N1/H7 cells expressing WT, AAA (phosphorylation deficient), or EEE (gain of function) mutants were treated with 100 nM ABT-737 for 48 hr, and apoptosis
was determined by Annexin positivity and mitochondrial membrane potential loss (TMRM). Equal levels of transfected BCL-2 in these cells were assured by
immunoblotting. Results are expressed as mean 6 SEM of three independent experiments.
E: DMSO- or ABT-treated NSF.N1/H7 WT, AAA, or EEE cells were lysed in buffer containing 0.5% NP-40. Immunoprecipitation was performed with an anti-BAX
antibody and examined for the presence of BCL-2. The amount of BAX immunoprecipitated from each sample was determined by anti-BAX antibody.
Association of endogenous BCL-2 with BAX was recently confirmed in these cells by comparing 1% CHAPS lysis buffer with 0.5% NP-40 lysis buffer (Deng
et al., 2006). The intensity of the bands was quantitated by densitometry and expressed as a percentage of BAX/BCL-2 relative to control.constructs containing shRNA against transcript 1 of the MCL-1
gene encoding the long isoform 1 gene product and a GFP re-
porter gene resulted in a 63% reduction of MCL-1 protein ex-
pression (Figure 4D). When these MCL-1-depleted cells were
treated with ABT-737, impressive apoptosis was induced, as
compared to mock-transfected cells or cells transfected with
irrelevant shRNA, which were resistant to ABT-737 (Figures
4E). These experiments established MCL-1 as a major resis-
tance factor to ABT-737.
ABT-737 induces apoptosis and selectively inhibits
colony formation of primary AML cells
The effect of ABT-737 on primary AML blast cells was tested by
measuring clonogenic AML cell growth in the CFU-blast assay.380All samples were obtained from relapsed/refractory AML pa-
tients (Table S1). Colony formation was significantly reduced to
18% 6 9% at 100 nM and to only 7% 6 4% at 250 nM (p <
0.05) (Figure 5A), with IC50s between 1.4 nM and 103.2 nM.
BCL-2 expression did not showsignificant variations in this sam-
ple set (Figure 5B) and did not correlate with the ability to inhibit
colony formation (R2 = 0.01, p = 0.87). In contrast, MCL-1 levels
varied 10-fold among different samples and inversely correlated
with IC50 for inhibition of clonogenicity (R
2 = 0.96, p = 0.003).
Importantly, only minimal inhibition of colony formation by
normal bone marrow cells (n = 3) was observed at up to 250 nM
ABT-737 (p>0.05) (Figures 5C–5E). Thedifference in inhibition of
AML and normal GM-progenitor cells was highly significant (p <
0.001). MCL-1 protein was highly expressed in cell lysate fromCANCER CELL NOVEMBER 2006
A R T I C L EFigure 4. Suppression of MCL-1 expression en-
hances ABT-737-induced apoptosis
A: OCI-AML3 cells were treated with 1 mM ABT-
737, 10 mM PD98059, or their combination for 9
and 24 hr, and MCL-1 expression was deter-
mined by western blot analysis.
B: BIM, BAK, BAX, or BCL-2 were immunoprecipi-
tated from OCI-AML3 cells treated for the indi-
cated times with 250 nM ABT-737, and immuno-
precipitates were subjected to western blot
using anti-MCL-1 (BIM, BAK IP), anti-BCL-2 (BAX
IP), or anti-BIM (BCL-2 IP) antibodies. The amount
of BIM, BAX, BAX, or BCL-2 immunoprecipitated
from each sample was determined using the
respective antibodies.
C: Expression of BIM, BAX, BAX, and BCL-2 in cell
lysates prior to immunoprecipitation.
D and E: OCI-AML3 cells were infected with lenti-
viral MCL-1 siRNA, control vector (H1LV), or
scrambled siRNA as described in the Experimen-
tal Procedures. GFP-positive and -negative cells
were FACS sorted and treated with the indi-
cated concentrations of ABT. MCL-1 expression
was analyzed by western blotting (D). Induction
of apoptosis was analyzed by Annexin V/TMRM
flow cytometry (E). Results are expressed as
mean6 SEM of three independent experiments.CD34-enriched normal marrow sample (lane 1, Figure 5B), while
BCL-2 expression was low, consistent with published observa-
tions (Park et al., 1995; Andreeff et al., 1999). MCL-1 mRNA ex-
pression was significantly higher in normal hematopoietic pro-
genitor cells (n = 4) compared to AML blasts (n = 58) (Figure
5F; p < 0.016), consistent with the reported crucial role for
MCL-1 in normal hematopoiesis (Opferman et al., 2005).
Supporting the direct effects on AML progenitors, ABT-737
induced apoptosis (Annexin V positivity) in eight of nine CD34+
AML progenitor cells (Tables S2 and S3, samples 1–9). No differ-
ence in sensitivity to ABT-737-induced apoptosis was noted be-
tween newly diagnosed and relapsed/refractory patients, while
ABT-737 induced moderate apoptosis only in one out of four
normal CD34+ samples (Tables S2 and S3, samples 10–13),
confirming preferential apoptosis induction in leukemic but not
in normal progenitor cells.
High sensitivity of AML stem cells to ABT-737
Effective leukemia therapy has to target leukemia stem cells
to generate sustained responses. AML stem cells have beenCANCER CELL NOVEMBER 2006phenotypically defined as CD34+382123+ (Jordan et al., 2000).
In samples from six relapsed AML patients, the frequency of
these stem cells was as follows: 0.23%, 0.61%, 0.33%,
39.18%, 2.97%, and 1.51%, respectively (samples 1–6, Table
S4). AML samples were treated with ABT-737 (100 nM), Ara-C
(1 and 5 mM), or vehicle for 24 hr. Three of six samples (1, 2,
and 5) had 2.8%, 0%, and 0% surviving stem cells following
treatmentwithABT-737 (Figure 5H). Ara-C, at theconcentrations
used, was without exception less cytotoxic against AML stem
cells than ABT-737, and ABT-737 completely eliminated all
stem cells in one of the two Ara-C-resistant samples (Figures
5G and 5H). This demonstrates what appears to be an exquisite
sensitivity ofAMLstemcells toABT-737 inmostbut not all cases.
Antileukemia activity of ABT-737 in vivo
Next, the effects of in vivo administration of ABT-737 were ex-
amined in the conditional leukemia model driven by Raf-trans-
formedmyeloid cells (Konopleva et al., 2005). FDCP-DRaf1 cells
were infected with AdLux-F/RGD vector to monitor leukemia
dissemination by bioluminescence imaging (BLI) and injected381
A R T I C L EFigure 5. ABT-737 inhibits clonogenic progenitor growth and causes selective apoptosis in AML stem cells
A, C, D, and E: Results are expressed as the mean6 SEM of the percentage of colonies compared with the number in DMSO-treated control cells. Inhibition of
colonies (CFU) in AML bone marrow samples (n = 5) (A) and CFU-GM (C), BFU-E (D), and CFU-GEMM (E) in normal bone marrow samples (n = 3) in the presence
of increasing concentrations of ABT-737 (25, 50, 100, and 250 nM). Results are expressed as mean 6 SEM of three independent experiments. B: Western blot
analysis of BCL-2, BAX, and MCL-1 expression in five AML samples (sample numbers correspond to those in Figure 5A) and in one CD34+-enriched sample from
normal bone marrow used for clonogenic studies. Numbers represent densitometry quantitation of the intensity of the bands normalized to GAPDH expression
in each sample and to the levels in HL-60 cells (=1). IC50s for AML samples were calculated based on the inhibition of the colony-forming ability of AML blasts
using CalcuSyn. F: Abundance of MCL-1 transcript was measured in samples from 58 AML samples and from 4 normal marrow CD34+ cells by real-time PCR,
and results are reported as the mean number of transcripts per hundred transcripts of b-2-microglobulin. Error bars denote the standard error of the mean. G:
Cells from a primary AML sample were treated with DMSO (control), 100 nM ABT-737, or 1 mM Ara-C for 24 hr. Induction of apoptosis was measured by Annexin V
positivity on gated CD34+CD382CD123+ AML stem cells. H: Effects of ABT-737 and Ara-C on AML stem cells. The frequency of CD34+CD382CD123+ PS/Annexin
V+ cells was determined by multicolor flow cytometry. The percentage of nonapoptotic (Annexin V2) stem cells was calculated after ABT-737 and Ara-C
treatment (number of stem cells in DMSO-treated cultures = 100%). In sample 1, cell numbers were insufficient to examine effects of Ara-C.intravenously (i.v.) into SCID mice. BLI demonstrated that ABT-
737 suppressed the leukemia burden by 48% and 53%at the 20
and 30mg/kg dose levels, respectively (p < 0.02; Figures 6A and
6B) and significantly extended survival of mice in this aggressive
leukemia model (median survival, 28–32.5 days compared to38219.5 days survival of controls, p < 0.01) (Figure 6C). Similar inhi-
bition of leukemia burden was observed in a human xenograft
leukemia model with KG-1 cells (Figures 6D and 6E). TUNEL
demonstrated induction of apoptosis in spleen and liver infil-
trated with leukemic cells (Figure S3). In healthy SCIDmice liver,CANCER CELL NOVEMBER 2006
A R T I C L EFigure 6. ABT-737 inhibits leukemia in vivo
Aand B: FD/GFPDRaf-1:ER luc cells were injected i.v. into SCID mice carrying b-estradiol-release pellets. Mice were treated with either ABT-737 (from days 1–21,
n = 8 per group) or vehicle (n = 8). On day 19, mice were imaged after D-luciferin injection. Serial images of representative mice are shown in A. Results were
averaged from the peak light-emitting exposure from each group and displayed as photons/s after normalizing for baseline luminescence intensity (B). Error
bars represent SEM.
C: Kaplan-Meier curves for these three groups of mice are shown. p value was determined by log-rank test.
D: Human leukemia luciferase-expressing KG-1 cells were injected i.v. into SCID mice, and leukemia dissemination was monitored by bioluminescence imag-
ing. Eighteen days post-cell injection, mice were treated with ABT-737 (n = 8 per group) or vehicle (n = 8). Serial images of representative mice are shown.
E: Results were averaged from the peak light-emitting exposure from each group and displayed as photons/s. Error bars represent SEM.kidney, and spleen remained histologically normal, and ABT-
737 treatment did not induce significant abnormalities in blood
cell counts or serum chemistries, although platelet counts
tended to be lower in ABT-737-treated animals (p = 0.15;
Figure S4).
Discussion
The mechanism of action of many traditional anticancer drugs
involves programmed cell death and raises the possibility of de-
signing strategies aimed at enhancing apoptosis. While several
regulators of apoptosis are candidates for such strategies, BCL-
2 family proteins have assumed a central role. ABT-737 is repre-
sentative of a class of BH3 mimetics developed for this purpose
(Oltersdorf et al., 2005; Pellecchia and Reed, 2004). The results
presented here support the use of ABT-737 as an antileukemia
agent, as the compound potently kills AML-derived cell lines andCANCER CELL NOVEMBER 2006blast cells from AML patients. Most importantly, our results
demonstrated killing of leukemic progenitors (CFU) and stem
cells (CD34+382123+), a critical property of any truly innovative
treatment for leukemias and cancer. Normal progenitor cells
were remarkably resistant to ABT-737, suggesting a very favor-
able therapeutic window. In contrast, Ara-C, the most active cy-
totoxic agent used in AML therapy, was less effective against
AML stem cells, providing excellent rationale for combination
approaches. Our data in aggressive murine and human xeno-
graft leukemia models clearly suggest that ABT-737 is effective
in vivo, in the absence of unwanted side effects on normal tis-
sues. These findings provide rationale for the development of
ABT-737 or related compounds for the treatment of AMLs.
Our mechanistic studies suggest that the cellular composition
of BCL-2 family proteins critically determines sensitivity to ABT-
737. It was recently postulated that MCL-1 and/or BFL-1 might
account for resistance to ABT-737 (Cory and Adams, 2005).383
A R T I C L EFigure 7. Mechanisms of sensitivity and resis-
tance to ABT-737
In sensitive cells with low or absent levels of MCL-
1 (left panel), BAK, BAX, and ‘‘activating’’ BH3-
only proteins, including BIM and possibly other
unidentified BH3-only proteins, are bound and
neutralized by BCL-2 prosurvival proteins. ABT-
737 displaces active BAK from BCL-XL, BAX from
BCL-2, or BIM/BH3-only protein from BCL-2. This is
followed by activation of freed BAX by BAK or
BH3-only proteins, MPT, caspase activation,
and apoptosis. In ABT-resistant cells expressing
high MCL-1 levels and/or phospho-BCL-2 (right
panel), both BAK and the ‘‘activating’’ BH3-
only proteins are sequestered by MCL-1 in addi-
tion to BCL-2 and BCL-XL prosurvival proteins.
ABT-737 fails to displace BAX from phosphory-
lated BCL-2, and BAK/BIM (or other BH3-only pro-
teins) remains bound and inactivated by MCL-1,
thus hindering BAX/BAK activation and promot-
ing cell survival.Our FPA results and coimmunoprecipitation experiments con-
firmed the inability of ABT-737 to inhibit binding of BIM or BAK
to MCL-1, and resistance to ABT-737 appears to correlate
with high MCL-1 expression in AML cell lines (Figure 1B), in
a subset of primary AML samples (Figure 5B) and in normal
CD34+ progenitor cells (Figures 5B and 5F). Downregulation of
MCL-1 by siRNA (Figure 4E) resulted in striking sensitization to
ABT-737. Thus, future small molecule inhibitors targeting
MCL-1 would be expected to act synergistically with ABT-737.
However, MCL-1 inhibitors may also target normal leukemic
stem cells, as MCL-1 has recently been shown to be a critical
regulator of early hematopoietic development in mice (Opfer-
man et al., 2005), consistent with our expression data in human
CD34+ cells (Figure 5E). In the absence ofMCL-1 small molecule
inhibitors, the MEK/ERK inhibitor PD98059 proved effective
at both suppressing MCL-1 expression (Figure 4A) and acting
synergistically in an unprecedented manner with ABT-737
(Figure 3C). We propose that, in AML cells with constitutive ac-
tivation of MAPK/ERK signaling, MCL-1 expression is largely
dependent on this pathway; hence inhibition of ERK activation
with MEK inhibitors may overcome resistance to ABT-737. Im-
portantly, we and others have shown complete lack of phos-
pho-ERK expression in normal progenitor cells (Milella et al.,
2001), while activation of ERK signaling confers poor survival
in AML (Kornblau et al., 2006).
Synergistic use of MEK/ERK inhibitors and ABT-737 has the
added advantage of blocking ERK’s role as a BCL-2 kinase (Fig-
ure 3B). We demonstrated that BCL-2 phosphorylation abro-
gates the activity of ABT-737 cells expressing a phosphomi-
metic mutant of the serine 70 phosphorylation site of BCL-2
were extremely resistant (Figure 3D). Of importance, we recently
reported phosphorylation of BCL-2 in primary AML samples,
and its negative impact on patient prognosis (Kurinna et al.,
2006). BCL-2 phosphorylation at serine 70 promotes heterodi-
merization with BAX (Ito et al., 1997). We therefore postulate
that phosphorylation-induced conformational changes in BCL-2384may impede access of ABT-737 to the BH3 binding groove, a
hypothesis currently under investigation.
Molecular analysis of apoptotic events initiated by ABT-737
suggested several mechanisms of sensitivity and resistance to
ABT-737 (Figure 7). The existing functional models acknowl-
edge the criticality of BAX and BAK for the execution of apopto-
sis, which was confirmed by our finding that MEF cells devoid of
BAX or BAK are resistant to ABT-737. Coimmunoprecipitation
experiments demonstrated that, in leukemic but not in HeLa
cells, BAX and BCL-2 form complexes, and that these com-
plexes are disrupted upon exposure to ABT-737. Our data fur-
ther showed that in leukemic cells, perhaps in contrast to other
cell types, a large fraction of BAX is associated with mitochon-
dria. Identical results were reported in other studies (Letai
et al., 2002; Deng et al., 2006), although this cell type-specific
phenomenon is not widely acknowledged in the literature. It re-
mains unclear, however, whether mitochondria-localized BAX is
already activated. While a recent report demonstrated the exis-
tence of BCL-2-inhibitable autoactivation of mitochondrial
membrane-bound BAX (Tan et al., 2006), we were unable to de-
tect it in healthy cells (Figure 2D). In addition, no association of
BAX with MCL-1 was detected in ABT-resistant cells, suggest-
ing involvement of additional protein(s) capable of activating
BAX in sensitive cells that are sequestered and inactivated by
MCL-1 in resistant cells. Of all BH3-only proteins examined,
only tBID and BIM are known to act as direct ‘‘activators’’ of
BAX and BAK (Letai et al., 2002). We first focused on BIM, which
has recently emerged as being critical for hematopoiesis (Bouil-
let et al., 1999) and is localized at the mitochondria of hemato-
poietic cells (Zhu et al., 2004; Harada et al., 2004; and
Figure 2E), but not other cell types (Puthalakath et al., 1999). Us-
ing synthetic peptides (Figure 1A) and coimmunoprecipitation
studies (Figures 4B), we indeed demonstrated the ability of
ABT-737 to disrupt BCL-2/BIM interactions. However, BIM
knockdown did not reduce ABT-triggered apoptosis. While we
did not achieve complete BIM silencing in hematopoietic cells,CANCER CELL NOVEMBER 2006
A R T I C L Ewhich are notoriously difficult to transfect, a recent report sug-
gests that other types of cell death may proceed independent
of BIM (Ekert et al., 2006), in sharp contrast to complete resis-
tance of cells deficient in BAX and BAK. Furthermore, ABT-
737 was shown to dramatically increase Imatinib-induced killing
of bcr-abl-transformedhematopoietic cells fromBIM2/2BAD2/2
knockout mice (Kuroda et al., 2006), thus arguing against
the criticality of BIM in ABT-737-induced apoptosis and BAX ac-
tivation. While we did not examine the role of tBID in ABT-737-
induced cell death, BID requires either cleavage via activated
caspase-8 into truncated tBID (Clohessy et al., 2006) or mem-
brane targeting (Oh et al., 2006) to serve as an activating BH3
protein. Our studies in caspase-8-deficient Jurkat cells docu-
mented undiminished ABT-737-induced apoptosis (Figure S5),
arguing against the role of caspase-8 and hence tBID in apopto-
sis induction by this agent. These findings also do not support
the recently proposed model of cell death that implies require-
ments of ‘‘stress’’ to engage the direct activators of BAX and
BAK (i.e., BIM or tBID) in cells that are ‘‘addicted’’ to the antia-
poptotic BCL-2 proteins (Certo et al., 2006). Alternatively, mito-
chondrially localized BAK may play a principal role in sensitivity
to ABT-737: BAK binds BCL-XL and MCL-1 and can assume
a BH3-exposed, active conformation in healthy cells, which is
kept incheckbyMCL-1/BCL-XL (Willis et al., 2005). InHL-60cells
with low endogenous MCL-1, we failed to detect MCL-1/BAK
association, implying that neutralization of BCL-XL by ABT-737
triggers apoptosis through activated BAK in cooperation with
BAX (Figure S2). In contrast, in resistant OCI-AML3 cells overex-
pressing MCL-1, BAK was tightly associated with MCL-1, and
ABT-737 was unable to disrupt this interaction (Figure 4B). Fur-
ther, BAX-expressing MEF cells deficient in BAK were resistant
to ABT-737 (Figure 2G), and depletion of BAK by siRNA in BAX-
expressing HL-60 cells profoundly inhibited mitochondrial de-
polarization caused by ABT (Figure 2H). These findings indicate
that BAK is indeed participating in apoptosis of sensitive cells.
While these hypotheses warrant further investigations, find-
ings presented here strongly suggest that cellular abundance
and mitochondrial composition of certain BCL-2 family proteins
define patterns of sensitivity or resistance to BH3 mimetics. Our
studies define hematologic malignancies as tumors exquisitely
sensitive to ABT-737 as a single agent, although elevated
MCL-1 expression and basal BCL-2 phosphorylation may con-
tribute to resistance. In cases where ERK signaling is antiapop-
totic, bothMCL-1 expression and phosphorylation of BCL-2 can
be blocked by ERK inhibitors. Alternatively, combinations with
traditional chemotherapeutic agents may overcome resistance
in certain cases, one possible mechanism being MCL-1 degra-
dation. In summary, the findings presented here strongly sug-
gest that ABT-737 will be an effective antineoplastic agent and
a potent weapon in the anti-AML arsenal.
Experimental procedures
Reagents and antibodies
ABT-737 was synthesized as described previously (Oltersdorf et al., 2005).
Tetramethylrhodamine methyl ester (TMRM) was purchased from Molecular
Probes (Eugene, OR). Annexin V FITCwas purchased fromRoche Diagnostic
Co. (Indianapolis, IN). Mouse IgG1 FITC, IgG1 PE, and CD34 PE were pur-
chased from BD Biosciences (San Jose, CA). Caspase-3, -8, and -9 (anti-
human and anti-mouse), phospho-BCL-2 (S-70), and phospho-ERK 1/2
antibodies were purchased from Cell Signaling Technologies Inc. (Beverly,
MA); the cytochrome c, BAX, BCL-2 (6C8), and MCL-1 antibodies wereCANCER CELL NOVEMBER 2006from BD Biosciences; the BCL-2 antibodies were from Dako (Carpinteria,
CA); BAK antibodies were from Upstate (Lake Placid, NY) and Calbiochem
(Ab-1); and the BIM antibody (22-40) was from Calbiochem (La Jolla, CA).
ERK 2 antibody and control anti-rat IgG, anti-rabbit, or anti-Syrian hamster
isotype-matched control antibodies were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA), BAX 2D2 and BAX clone 6A7 antibodies were
from Sigma Chemical Co., GAPDH antibody was from Chemicon Interna-
tional (Temecula, CA), and goat anti-mouse and goat anti-rabbit horseradish
peroxidase-conjugated secondary antibodies were from Bio-Rad (Hercules,
CA). Rat monoclonal anti-BIM (3C5) was kindly provided by Drs. L.A. O’Reilly
and A. Strasser (TheWalter and Eliza Hall Institute of Medical Research, Mel-
bourne, Australia), and polyclonal anti-human anti-BAX antibody was from
Dr. W.S. May (Ito et al., 1997). TUNEL labeling kit was purchased fromRoche
Diagnostics Corporation (Mannheim, Germany).
Cell lines and primary AML samples
U937, HL-60, KG-1, and NB4 cells were purchased from The American Type
Culture Collection (ATCC, Rockville, MD). OCI-AML3 cells were kindly pro-
vided by M.D. Minden (Ontario Cancer Institute, Toronto, ON, Canada),
and HCT116 BAX+/2 and BAX2/2 cells were provided by Dr. B. Vogelstein
(John Hopkins University, Baltimore, MD). WT, BAX, BAK, and DKO SV40-
MEFs were a kind gift of Dr. S.J. Korsmeyer (Howard Hughes Medical Insti-
tute, Harvard Medical School, Boston, MA). Various phospho mutants of the
murine IL-3-dependent cell line NSF/N1.H7 were constructed using site-
directed mutagenesis, as described (May et al., 1994).
Bone marrow or peripheral blood samples were obtained for in vitro
studies from patients with newly diagnosed or recurrent AML during routine
diagnostic work-up following informed consent. All studies performed with
human specimens were done with approval from the M.D. Anderson
Institutional Review Board. The clinical features of the patients are listed in
Tables S1–S4. Specimens from bone marrow transplant donors underwent
CD34+ separation to greater than 95% purity by positive-selection mag-
netic-bead sorting using a VarioMACS device (Miltenyi Biotec, Auburn,
CA). Cells were either used for colony assays or cultured in AIM-V medium
(Gibco Laboratories) supplemented with 5% FBS, 1 mM L-glutamine, and
50 mg/ml penicillin/streptomycin.
Flow cytometric analysis of apoptosis
Apoptosis was determined by the flow cytometric measurement of phospha-
tidylserine exposure using Annexin V FITC as described (Milella et al., 2001).
In the case of cells from patient samples, cells were stained with PE-labeled
anti-CD34 and Annexin V FITC. The mitochondrial transmembrane potential
(Dcm) was determined by measuring TMRM retention (red fluorescence)
(Kaufmann et al., 1998).
FPAs
To determine the binding affinity of GST-BCL-2 family proteins to the FITC-
conjugated BH3 domain of BIM (FITC-Ahx-DMRPEIWIAQELRRIGDEF
NAYYAR), FPAs were performed as described (Zhai et al., 2005). Briefly,
100 nM of GST-BCL-2 family fusion proteins were incubated with serial dilu-
tions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-BIM BH3 peptide
(FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) was added. Fluorescence
polarization was measured using an Analyst TM AD Assay Detection System
(LJL Biosystem, Sunnyvale, CA) after 10 min using the 96-well black plate
(Greiner bio-one). IC50s were determined using GraphPad Prism software
(GraphPad, Inc., San Diego, CA).
BAX conformational change
Cells (5 3 106) were lysed in buffer (125 ml) containing 150 mM NaCl, 10 mM
HEPES (pH 7.4), 1% CHAPS, and protease inhibitors. Protein lysates were
subjected to immunoprecipitation using anti-BAX antibody clone 6A7, which
recognizes conformationally changed BAX protein. Supernatants and im-
munoprecipitates were then resuspended in SDS gel-loading buffer and
subjected to western blot analysis with anti-BAX antibody (Craig, 2002).
Mitochondrial cytochrome c release
HL-60 mitochondria were isolated as described previously (Samudio et al.,
2006). Mitochondrial suspensions (0.8 mg/ml protein) were energized with
succinate in the presence of rotenone and treatedwith DMSOor various con-
centrations of ABT-737 for 15 min at room temperature. Mitochondria were385
A R T I C L Ecollected by centrifugation at 14,000 rpm for 5 min, and the presence of
cytochrome c was evaluated by western blotting of the mitochondrial pellet
and the supernatant.
Quantitative real-time PCR
Bone marrow and peripheral blood samples were lysed with RNA Stat 60
(Tel-Test, Friendswood, TX). Real-time PCR was done using an ABI Prism
7700 instrument. As primer and probe sets to detect MCL-1 and housekeep-
ing gene b-2-microglobulin, we used TaqMan Gene Expression Assays
Hs0000172036_m1 and Hs99999907_m1 (for details, see the Supplemental
Experimental Procedures). The abundance of each transcript relative to that
of b-2-microglobulin was calculated as follows: relative expression (RE) =
100 3 2 exp [2DCt], where DCt is the mean Ct of the transcript of interest
less the mean Ct of the transcript for b-2-microglobulin.
siRNA transfection
For BIM knockdown, siRNAs were obtained as duplexes in purified and de-
salted form from Dharmacon. The sense strand of the siRNA silencing BIM
gene (BIM-siRNA) was GACCGAGAAGGUAGACAAUUGdTdT (Han et al.,
2005). A nonspecific control pool containing four pooled nonspecific siRNA
duplexes was used as a negative control (referred to as NS-siRNA, Dharma-
con-Upstate). For BAK knockdown, ON-TARGETplus SMARTpool and
siCONTROL Non-Targeting siRNA 1 were obtained from Dharmacon. Trans-
fection of leukemic cells was carried out by electroporation using the
Nucleofection system (Amaxa, Ko¨ln, Germany), following the manufacturer’s
instructions. The final concentration of siRNA was 67 nM. At the optimal time
of gene silencing monitored by western blot (24 hr posttransfection), various
concentrations of ABT-737 were added to the cells.
Preparation of lentiviral construct for shRNA MCL-1 knockdown
To downregulate the expression of MCL-1 by RNA interference, sense and
antisense oligonucleotides were designed to generate a short 19 bp hairpin
corresponding to nucleotides 2343–2361 of transcript variant 1 of the MCL-1
gene encoding the long isoform 1 gene product (GenBank accession number
NM 021960). As control, sense and antisense oligonucleotides were de-
signed to generate a 19 bp hairpin targeting the irrelevant sequence,
CGTACGCGGAATACTTCGA. The oligonucleotides were annealed and li-
gated into a self-inactivating lentiviral vector (Lois et al., 2002; Miyoshi
et al., 1998) under control of the HI promoter. The vector was also designed
to carry the GFP reporter gene under control of the human ubiquitin-C pro-
moter to monitor infection efficiency.
Each lentiviral shRNA construction was transfected into 293T cells using
FuGENE 6 (Roche Diagnostics, Indianapolis, IN). Cells were monitored for
GFP fluorescence, and at 72 hr posttransfection, virus-containing superna-
tants were collected and used to infect OCI-AML3 cells. At 72 hr postinfec-
tion, the cells were sorted for GFP fluorescence, plated, and treated with
ABT-737.
AML blast colony assay and CFU-granulocyte-macrophage assays were
conducted as described (Milella et al., 2001) (for details, please refer to the
Supplemental Experimental Procedures).
Flow cytometric analysis of AML stem cells
The frequency of AML stem cells was determined as described (Jordan et al.,
2000). Onemillion total cells weremeasured per sample using a Becton Dick-
inson LSR II flow cytometer, and the frequency of CD34+382123+ cells was
calculated. Induction of apoptosis in AML stem cells was determined by
a four-color multiparametric flow cytometry assay using CD34 APC, CD38
PE Cy7, CD123 PE, and Annexin V FITC.
Statistics
Results are expressed as means 6 SEM of three separate replicate experi-
ments unless otherwise indicated. Levels of significance were evaluated by
a two-tailed paired Student’s t test, and p < 0.05 was considered significant.
Synergism, additive effects, and antagonism were assessed with the Chou-
Talay method (Chou and Talalay, 1984) and Calcusyn software (Biosoft, Fer-
guson, MO); the CI for each experimental combination was calculated. When
CI = 1, the equation represents the conservation isobologram and indicates
additive effects. CI values < 1.0 indicate an additive effect characteristic of
synergism.386Xenograft studies in Scid mice
All animal work was done in accordance with a protocol approved by the In-
stitutional Animal Care and Use Committee. We utilized a Raf-inducedmodel
of AML established in our laboratory (Konopleva et al., 2005). To generate
luc-expressing FD/DRaf-1:ER cells, they were infected with fiber-modified
adenoviral vector expressing firefly luciferase. Four- to six-week-old CB.17
Scid mice (Harlan Sprague Dawley, Madison, WI) were implanted with 1.7
mg, 60 day release, 17b-estradiol pellets (Innovative Research, Sarasota,
FL). The next day, 1 3 106 luciferase-expressing FD/DRaf-1:ER cells sus-
pended in 200 ml PBS were injected i.v. In a model of human leukemia xeno-
graft, 5 3 106 human leukemic luciferase-expressing KG-1 cells were in-
jected i.v. into Scid mice.
For intraperitoneal (i.p.) administration, 1 g ml21 stock solution of ABT-737
in DMSO was added to a mixture of 30% propylene glycol, 5% Tween 80,
65% D5W (5% dextrose in water) (pH 425; final concentration of DMSO%
1%). Mice injected with FD/DRaf-1:ER cells were treated with either ABT-
737 (20 and 30 mg/kg/mouse every day i.p. for 21 days starting on day 1
post-cell injection (n = 9–10 mice per group) or vehicle or left untreated
(control); mice injected with human KG-1 cells were treated with 30 mg/kg
ABT-737 starting on day 18 post-cell injection. For noninvasive imaging of
FD/DRaf-1:ER-luc cells, anesthetized mice were injected with 150 mg/kg
of D-luciferin (potassium salt, Xenogen Corp., Alameda, CA) and placed for
imaging in the In Vivo Imaging System (IVIS, Xenogen) with total imaging
time of 2 min. Total body bioluminescence was quantified as described
(Konopleva et al., 2005).
Mice were sacrificedwhen they becamemoribund or unable to obtain food
or water or if they lost >20% of their body weight. Effects of ABT-737 on
survival were estimated with the method of Kaplan and Meier, and log-rank
statistics was used to test for differences in survival distributions.
Other procedures are in the Supplemental Data.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures, five
supplemental figures, and four supplemental tables and can be found with
this article online at http://www.cancercell.org/cgi/content/full/10/5/375/
DC1/.
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